145 related articles for article (PubMed ID: 32111572)
1. Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.
Bhatt VR; Shostrom V; Holstein SA; Al-Kadhimi ZS; Maness LJ; Berger A; Armitage JO; Gundabolu K
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e239-e258. PubMed ID: 32111572
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of Charlson Comorbidity Index to Predict Early Mortality and Overall Survival in Older Patients With Acute Myeloid Leukemia.
Dhakal P; Shostrom V; Al-Kadhimi ZS; Maness LJ; Gundabolu K; Bhatt VR
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):804-812.e8. PubMed ID: 32739312
[TBL] [Abstract][Full Text] [Related]
3. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
4. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
[TBL] [Abstract][Full Text] [Related]
5. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
6. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.
Reid JH; Marini BL; Benitez LL; Pettit K; Bixby DL; Burke P; Perissinotti AJ
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):393-400.e1. PubMed ID: 33612433
[TBL] [Abstract][Full Text] [Related]
7. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).
Tawfik B; Pardee TS; Isom S; Sliesoraitis S; Winter A; Lawrence J; Powell BL; Klepin HD
J Geriatr Oncol; 2016 Jan; 7(1):24-31. PubMed ID: 26527394
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
Tawfik B; Sliesoraitis S; Lyerly S; Klepin HD; Lawrence J; Isom S; Ellis LR; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee T
Ann Hematol; 2014 Jan; 93(1):47-55. PubMed ID: 24149914
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
10. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Miyawaki S; Ohtake S; Fujisawa S; Kiyoi H; Shinagawa K; Usui N; Sakura T; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
Blood; 2011 Feb; 117(8):2366-72. PubMed ID: 21190996
[TBL] [Abstract][Full Text] [Related]
12. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
Hou HA; Tzeng HE; Liu HY; Chou WC; Tien HF; Chien LN
Ann Hematol; 2022 Jan; 101(1):109-118. PubMed ID: 34643769
[TBL] [Abstract][Full Text] [Related]
14. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
15. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
Reagan JL; Sullivan MR; Winer ES; Lansigan F; Cardin MS; Castillo JJ
Leuk Res; 2015 Aug; 39(8):812-7. PubMed ID: 26045177
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center.
Jaime-Pérez JC; Padilla-Medina JR; Fernández LT; Herrera-Garza JL; Gutiérrez-Aguirre CH; Tarín-Arzaga L; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):286-292. PubMed ID: 29478946
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Huang YJ; Zhang JH; Dong CX; Kang JM; Hou YF; Zhang YF; Qi K; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
[TBL] [Abstract][Full Text] [Related]
20. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J
Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
